Ritodrina [Inn-Spanish]
Brand names,
Ritodrina [Inn-Spanish]
Analogs
Ritodrina [Inn-Spanish]
Brand Names Mixture
Ritodrina [Inn-Spanish]
Chemical_Formula
C17H21NO3
Ritodrina [Inn-Spanish]
RX_link
No information avaliable
Ritodrina [Inn-Spanish]
fda sheet
Ritodrina [Inn-Spanish]
msds (material safety sheet)
Ritodrina [Inn-Spanish]
Synthesis Reference
Belg. pat. 660.244 (1965 to N.V. Philips), C.A. 63, 17965h (1965) corresp to Claassen et al., U.S. pat. 3,410,944 (1968 to No. Am. Philips)
Ritodrina [Inn-Spanish]
Molecular Weight
287.354 g/mol
Ritodrina [Inn-Spanish]
Melting Point
88-90 oC
Ritodrina [Inn-Spanish]
H2O Solubility
Complete
Ritodrina [Inn-Spanish]
State
Solid
Ritodrina [Inn-Spanish]
LogP
2.588
Ritodrina [Inn-Spanish]
Dosage Forms
Solution for IV; Capsule (extended-release); Tablet; Intramuscular injection
Ritodrina [Inn-Spanish]
Indication
For the treatment and prophylaxis of premature labour
Ritodrina [Inn-Spanish]
Pharmacology
Beta-2 adrenergic receptors are located at sympathetic neuroeffector junctions of many organs, including uterus. Ritodrine is beta-2 adrenergic agonist. It stimulates beta-2 adrenergic receptor, increases cAMP level and decreases intracellular calcium concentration. The decrease of calcium concentration leads to a relaxation of uterine smooth muscle.
Ritodrina [Inn-Spanish]
Absorption
No information avaliable
Ritodrina [Inn-Spanish]
side effects and Toxicity
LD50=64mg/kg (mice, IV); LD50=540 mg/kg (mice, oral); LD50=85 mg/kg (rat, IV)
Ritodrina [Inn-Spanish]
Patient Information
Ritodrina [Inn-Spanish]
Organisms Affected
Humans and other mammals